Evoke Pharma Inc (NASDAQ:EVOK)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $1.22, but opened at $1.33. Evoke Pharma shares last traded at $1.32, with a volume of 4,437 shares traded.
A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “hold” rating on shares of Evoke Pharma in a research report on Friday, August 9th. ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.
The stock’s 50-day moving average is $0.91 and its two-hundred day moving average is $0.84. The stock has a market cap of $32.23 million, a P/E ratio of -2.67 and a beta of 1.53.
An institutional investor recently bought a new position in Evoke Pharma stock. Citadel Advisors LLC purchased a new stake in shares of Evoke Pharma Inc (NASDAQ:EVOK) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 59,047 shares of the specialty pharmaceutical company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned approximately 0.25% of Evoke Pharma as of its most recent SEC filing. Institutional investors own 5.70% of the company’s stock.
Evoke Pharma Company Profile (NASDAQ:EVOK)
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Read More: What is meant by holder of record?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.